Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer
Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Hortobágyi, Gabriel N. [verfasserIn] Buzdar, Aman U. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1993 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Drugs - Berlin [u.a.] : Springer, 1971, 45(1993), Suppl 2 vom: Mai, Seite 10-19 |
|---|---|
| Übergeordnetes Werk: |
volume:45 ; year:1993 ; number:Suppl 2 ; month:05 ; pages:10-19 |
| Links: |
|---|
| DOI / URN: |
10.2165/00003495-199300452-00004 |
|---|
| Katalog-ID: |
SPR033162395 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033162395 | ||
| 003 | DE-627 | ||
| 005 | 20230519071516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1993 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00003495-199300452-00004 |2 doi | |
| 035 | |a (DE-627)SPR033162395 | ||
| 035 | |a (SPR)00003495-199300452-00004-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Hortobágyi, Gabriel N. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer |
| 264 | 1 | |c 1993 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. | ||
| 650 | 4 | |a Breast Cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Doxorubicin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adjuvant Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metastatic Breast Cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Primary Breast Cancer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Buzdar, Aman U. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Berlin [u.a.] : Springer, 1971 |g 45(1993), Suppl 2 vom: Mai, Seite 10-19 |w (DE-627)320609413 |w (DE-600)2021165-X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:1993 |g number:Suppl 2 |g month:05 |g pages:10-19 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00003495-199300452-00004 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 45 |j 1993 |e Suppl 2 |c 05 |h 10-19 | ||
| author_variant |
g n h gn gnh a u b au aub |
|---|---|
| matchkey_str |
article:11791950:1993----::rsnsauoatrccieiteduatram |
| hierarchy_sort_str |
1993 |
| bklnumber |
44.40 44.38 |
| publishDate |
1993 |
| allfields |
10.2165/00003495-199300452-00004 doi (DE-627)SPR033162395 (SPR)00003495-199300452-00004-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Hortobágyi, Gabriel N. verfasserin aut Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. Breast Cancer (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Adjuvant Chemotherapy (dpeaa)DE-He213 Metastatic Breast Cancer (dpeaa)DE-He213 Primary Breast Cancer (dpeaa)DE-He213 Buzdar, Aman U. verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 45(1993), Suppl 2 vom: Mai, Seite 10-19 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 https://dx.doi.org/10.2165/00003495-199300452-00004 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 45 1993 Suppl 2 05 10-19 |
| spelling |
10.2165/00003495-199300452-00004 doi (DE-627)SPR033162395 (SPR)00003495-199300452-00004-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Hortobágyi, Gabriel N. verfasserin aut Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. Breast Cancer (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Adjuvant Chemotherapy (dpeaa)DE-He213 Metastatic Breast Cancer (dpeaa)DE-He213 Primary Breast Cancer (dpeaa)DE-He213 Buzdar, Aman U. verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 45(1993), Suppl 2 vom: Mai, Seite 10-19 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 https://dx.doi.org/10.2165/00003495-199300452-00004 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 45 1993 Suppl 2 05 10-19 |
| allfields_unstemmed |
10.2165/00003495-199300452-00004 doi (DE-627)SPR033162395 (SPR)00003495-199300452-00004-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Hortobágyi, Gabriel N. verfasserin aut Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. Breast Cancer (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Adjuvant Chemotherapy (dpeaa)DE-He213 Metastatic Breast Cancer (dpeaa)DE-He213 Primary Breast Cancer (dpeaa)DE-He213 Buzdar, Aman U. verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 45(1993), Suppl 2 vom: Mai, Seite 10-19 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 https://dx.doi.org/10.2165/00003495-199300452-00004 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 45 1993 Suppl 2 05 10-19 |
| allfieldsGer |
10.2165/00003495-199300452-00004 doi (DE-627)SPR033162395 (SPR)00003495-199300452-00004-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Hortobágyi, Gabriel N. verfasserin aut Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. Breast Cancer (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Adjuvant Chemotherapy (dpeaa)DE-He213 Metastatic Breast Cancer (dpeaa)DE-He213 Primary Breast Cancer (dpeaa)DE-He213 Buzdar, Aman U. verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 45(1993), Suppl 2 vom: Mai, Seite 10-19 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 https://dx.doi.org/10.2165/00003495-199300452-00004 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 45 1993 Suppl 2 05 10-19 |
| allfieldsSound |
10.2165/00003495-199300452-00004 doi (DE-627)SPR033162395 (SPR)00003495-199300452-00004-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Hortobágyi, Gabriel N. verfasserin aut Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. Breast Cancer (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Adjuvant Chemotherapy (dpeaa)DE-He213 Metastatic Breast Cancer (dpeaa)DE-He213 Primary Breast Cancer (dpeaa)DE-He213 Buzdar, Aman U. verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 45(1993), Suppl 2 vom: Mai, Seite 10-19 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 https://dx.doi.org/10.2165/00003495-199300452-00004 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 45 1993 Suppl 2 05 10-19 |
| language |
English |
| source |
Enthalten in Drugs 45(1993), Suppl 2 vom: Mai, Seite 10-19 volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 |
| sourceStr |
Enthalten in Drugs 45(1993), Suppl 2 vom: Mai, Seite 10-19 volume:45 year:1993 number:Suppl 2 month:05 pages:10-19 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Breast Cancer Doxorubicin Adjuvant Chemotherapy Metastatic Breast Cancer Primary Breast Cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Drugs |
| authorswithroles_txt_mv |
Hortobágyi, Gabriel N. @@aut@@ Buzdar, Aman U. @@aut@@ |
| publishDateDaySort_date |
1993-05-01T00:00:00Z |
| hierarchy_top_id |
320609413 |
| dewey-sort |
3610 |
| id |
SPR033162395 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033162395</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071516.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003495-199300452-00004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033162395</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003495-199300452-00004-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hortobágyi, Gabriel N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxorubicin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvant Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastatic Breast Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Primary Breast Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buzdar, Aman U.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1971</subfield><subfield code="g">45(1993), Suppl 2 vom: Mai, Seite 10-19</subfield><subfield code="w">(DE-627)320609413</subfield><subfield code="w">(DE-600)2021165-X</subfield><subfield code="x">1179-1950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:10-19</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003495-199300452-00004</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">1993</subfield><subfield code="e">Suppl 2</subfield><subfield code="c">05</subfield><subfield code="h">10-19</subfield></datafield></record></collection>
|
| author |
Hortobágyi, Gabriel N. |
| spellingShingle |
Hortobágyi, Gabriel N. ddc 610 bkl 44.40 bkl 44.38 misc Breast Cancer misc Doxorubicin misc Adjuvant Chemotherapy misc Metastatic Breast Cancer misc Primary Breast Cancer Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer |
| authorStr |
Hortobágyi, Gabriel N. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)320609413 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-1950 |
| topic_title |
610 ASE 44.40 bkl 44.38 bkl Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer Breast Cancer (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Adjuvant Chemotherapy (dpeaa)DE-He213 Metastatic Breast Cancer (dpeaa)DE-He213 Primary Breast Cancer (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.40 bkl 44.38 misc Breast Cancer misc Doxorubicin misc Adjuvant Chemotherapy misc Metastatic Breast Cancer misc Primary Breast Cancer |
| topic_unstemmed |
ddc 610 bkl 44.40 bkl 44.38 misc Breast Cancer misc Doxorubicin misc Adjuvant Chemotherapy misc Metastatic Breast Cancer misc Primary Breast Cancer |
| topic_browse |
ddc 610 bkl 44.40 bkl 44.38 misc Breast Cancer misc Doxorubicin misc Adjuvant Chemotherapy misc Metastatic Breast Cancer misc Primary Breast Cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Drugs |
| hierarchy_parent_id |
320609413 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Drugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)320609413 (DE-600)2021165-X |
| title |
Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer |
| ctrlnum |
(DE-627)SPR033162395 (SPR)00003495-199300452-00004-e |
| title_full |
Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer |
| author_sort |
Hortobágyi, Gabriel N. |
| journal |
Drugs |
| journalStr |
Drugs |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1993 |
| contenttype_str_mv |
txt |
| container_start_page |
10 |
| author_browse |
Hortobágyi, Gabriel N. Buzdar, Aman U. |
| container_volume |
45 |
| class |
610 ASE 44.40 bkl 44.38 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Hortobágyi, Gabriel N. |
| doi_str_mv |
10.2165/00003495-199300452-00004 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
present status of anthracyclines in the adjuvant treatment of breast cancer |
| title_auth |
Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer |
| abstract |
Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. |
| abstractGer |
Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. |
| abstract_unstemmed |
Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
Suppl 2 |
| title_short |
Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer |
| url |
https://dx.doi.org/10.2165/00003495-199300452-00004 |
| remote_bool |
true |
| author2 |
Buzdar, Aman U. |
| author2Str |
Buzdar, Aman U. |
| ppnlink |
320609413 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00003495-199300452-00004 |
| up_date |
2024-07-03T16:59:03.071Z |
| _version_ |
1803577923281616896 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033162395</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071516.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003495-199300452-00004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033162395</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003495-199300452-00004-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hortobágyi, Gabriel N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Anthracyclines represent the most active cytotoxic agents against metastatic breast cancer. The introduction of these drugs into the adjuvant therapy of breast cancer was slow because of concern related to chronic toxicities. However, there is clinical evidence of the safety and efficacy of doxorubicin-containing adjuvant regimens with follow-up periods that now approach 19 years. Adjuvant chemotherapy trials performed at the University of Texas M.D. Anderson Cancer Center demonstrate that doxorubicin can be administered in the adjuvant setting with tolerable and reversible acute side effects, and minimal long term toxicity. Over the last 15 years, a number of prospective randomised trials have compared doxorubicin-containing regimens versus those not containing doxorubicin in the adjuvant therapy of early breast cancer. Several of these trials have demonstrated disease-free survival benefit of the doxorubicin-containing regimens; some have also shown a definite overall survival gain. Several other trials in progress will need additional follow-up for definitive analysis. Thus, doxorubicin-containing adjuvant chemotherapy is effective, tolerable, and safe for adjuvant therapy of breast cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxorubicin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvant Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastatic Breast Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Primary Breast Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buzdar, Aman U.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1971</subfield><subfield code="g">45(1993), Suppl 2 vom: Mai, Seite 10-19</subfield><subfield code="w">(DE-627)320609413</subfield><subfield code="w">(DE-600)2021165-X</subfield><subfield code="x">1179-1950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:10-19</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003495-199300452-00004</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">1993</subfield><subfield code="e">Suppl 2</subfield><subfield code="c">05</subfield><subfield code="h">10-19</subfield></datafield></record></collection>
|
| score |
7.400508 |